Clinical worsening also occurred less frequently with treprostinil ...
The pooled global incidence and prevalence of progressive pulmonary fibrosis appear higher in the US than in Europe and South Korea.
Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...
Randomized trial shows no difference from sham control ...
Nintedanib treatment reduces the levels of circulating cancer antigen 125 in patients with progressive pulmonary fibrosis.
BACKGROUND: Right ventricular failure drives both morbidity and mortality in pulmonary arterial hypertension (PAH), but the mechanism of transition from compensated right ventricle (cRV) to ...